VistaGen Therapeutics, Inc. (VTGN)

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference